September 2026 — page 3
Novo Nordisk’s Wegovy provides an established obesity benchmark
Semaglutide’s original weight-management approval and STEP 1 evidence offer a reference point for newer development programs.
AbbVie’s Skyrizi extends its IL-23 role into ulcerative colitis
The approved indication rests on distinct induction and maintenance studies, with longer follow-up continuing.
Lilly’s triple agonist retatrutide heads toward a planned US filing
Phase 3 readouts support a submission target for early 2027, while regulatory review and longer-term questions remain ahead.
Roche and Zealand advance petrelintide’s amylin approach to obesity
Phase 2 findings and a planned combination study build the evidence for an alternative to incretin-only treatment.
Roche and Zealand plan a two-mechanism obesity combination trial
The Phase 2 design pairs petrelintide with enicepatide and compares the combination with its components and placebo.
Lilly’s Foundayo brings oral GLP-1 treatment into the obesity market
Orforglipron received FDA approval in April 2026, adding an oral option alongside injectable medicines.
Lilly and Novo set the backdrop for a changing obesity pipeline
Nine selected compounds span approved treatments, new mechanisms and dosing schedules; unlike trials cannot establish a simple efficacy ranking.
Abivax’s obefazimod nears a planned US filing after Phase 3 readouts
July financing supports the developer’s next steps, but its year-end application target and cash-runway forecast remain plans.
Lilly’s Omvoh follows induction with maintenance in ulcerative colitis
The approved IL-23 antibody starts with infusions and moves to injections, with maintenance evidence drawn from patients who first responded.
Amgen tests monthly obesity treatment with MariTide in Phase 3
The investigational therapy combines GLP-1 activation with GIP blockade; durability and tolerability remain central questions.
Pfizer’s Velsipity brings an oral option to ulcerative colitis
Etrasimod’s approval rests on placebo-controlled evidence, including a year-long study whose design differs from responder-only maintenance trials.
Roche’s enicepatide adds diabetes results as Phase 3 trials recruit
A 48-week Phase 2 readout broadens the obesity program’s evidence, while longer pivotal trials and a combination study address separate questions.
Teva and Sanofi take duvakitug into Phase 3 for ulcerative colitis
The TL1A antibody moves beyond responder-selected Phase 2 findings, backed by shared development costs and commercial rights.
Pfizer’s oral GLP-1 program ended with danuglipron’s discontinuation
A potential liver-injury case preceded the April 2025 decision; completed trial records do not signal an active program.
Kingfisher upgrades profit guidance as Screwfix drives growth
The home improvement retailer raised its adjusted pre-tax profit forecast to a range of £595 million to £635 million
Microsoft expands datacenter training
The cloud services provider extended its academy network to prepare local technicians for an infrastructure business that depends on skilled workers.
The Uneven Conversion of Earnings Into Cash
Acquired activity and lower capital spending explain part of a dramatic cash-flow improvement, while peer comparisons show why its recurring organic component remains unquantified.
AnaptysBio Records $177 Million Tax-Driven Profit
Jemperli global net sales reached $331 million in the three months ended June 30, 2026, as AZUR-1 data moved the FDA clock to February 2027.
Woodward to Move Santa Clarita Aerospace Production to Spartanburg
The energy-controls maker will shift military flight-control actuation to South Carolina and sell a smaller group of legacy products as it refines its manufacturing footprint.
Construction Partners Adds Roads, Inc. of NWF
The Florida Panhandle deal folds the contractor into C.W. Roberts to deepen CPI’s public and private infrastructure coverage in the region.
PTC Completes ST-920 Fabry Gene Therapy Purchase
The rare-disease company closed a competitive bankruptcy auction for a BLA-stage AAV program it plans to file in the fourth quarter.
Investor Group to Take Priority Technology Private in $1.6 Billion Cash Deal
Chairman Thomas Priore’s group will buy remaining Priority shares at $8.05, a 65% premium to the pre-proposal close, with Searchlight equity and a first-half 2027 close.
Elemental Royalty to Buy Orion in $290 Million Mixed Deal
The precious-metals royalty company said the eighth deal in twelve months is immediately accretive to NAV per share and adds three producing assets plus a Nevada silver stream.
DICK’S Completes $2.5 Billion Foot Locker Acquisition
The sporting-goods retailer closed the mixed cash-and-stock merger on Sept. 8, 2025, folding Foot Locker’s global store base into a standalone unit.
FDA Approves Scholar Rock's ISEMBYLD
Scholar Rock Holding (SRRK) won approval for ISEMBYLD under BLA 761463, with the agency's status date of September 11, 2026.
Leadership Turnover Flags Operational Risk
Four U.S. companies are treating executive and board transitions as a live operational and financial risk, from interim co-CEOs at lululemon to severance at Lands' End.
Weathernews Posts Record Profit as AI Trims Staffing Costs
Weathernews reported net income of 3,806 million yen for the fiscal year ended May 2026, up 22.2% from a year earlier.
Regional Banks Split on CRE Growth as Deposit Costs Ease
A wave of second-quarter filings shows commercial real estate books expanding sharply at some regional lenders while deposit repricing and credit costs eased at others.
Catastrophe Loss Relief Drives Reinsurance Pricing Softening
RenaissanceRe's property book swung from a 148.7% combined ratio to 34.1% in a single year, and the relief is already showing up as give-back in reinsurance pricing.
Mercari reports record revenue and core operating profit
Group operating profit rose 57.7% to 43.905 billion yen.
Open Up Group's revenue fell 10.9% in fiscal 2026
Revenue at the technical-staffing and outsourcing group fell 10.9% to 167,483 million yen in the year ended June 30, 2026.
Maeda Kosen Posts Record Revenue and Profit for Fiscal 2026
Maeda Kosen reported revenue of 71,389 million yen for the fiscal year ended June 30, 2026, up 11.4% from a year earlier and a record high for the company.
H.I.G. Capital to Buy MISTRAS in $866 Million Cash Deal
The industrial asset-integrity firm will be taken private at $20.35 a share after a 40-day go-shop, with closing expected in late 2026 or early 2027.
Disney's Fubo Deal Lifts Streaming Revenue as Linear Erosion Spreads
Disney quantified how much of its subscription growth came from the Fubo transaction, while affiliate-dependent peers reported accelerating basic-subscriber losses and unchanged risk language on the pace of the shift.
Rubrik's 48% Cloud ARR Surge Leads Diverging Software Sector Growth
Cloud-metric disclosures across the sector show recurring revenue accelerating at some companies and cooling at others, even as risk-factor hedging on cloud adoption and renewal rates stayed largely unchanged.
Office CRE Stress Persists in Bank Filings as Kilroy Sees Gains
Community bank lenders keep flagging distressed office borrowers in central business districts even as one West Coast office landlord reports improving leasing activity.
Beazer's Margin Hit Highlights Builders' Cost and Rate Strain
A rapid March run-up in mortgage rates cut into one builder's spring selling season, while risk-factor language across the group kept flagging tariffs, labor and land costs as unresolved pressure points.
Kratos Backlog Nears $2.1 Billion as Defense Suppliers Diverge
Kratos Defense & Security Solutions posted the sharpest backlog gains in the group while several suppliers further down the chain flagged funding and program risk even as new contract wins accumulated.
Southwest Fares Jump 16.6% as Sabre Flags Mideast Booking Drag
Southwest Airlines disclosed record first-quarter revenue on a sharp fare increase, while Sabre and Wheels Up reported demand pressures tied to conflict abroad and shrinking private-jet flight volumes.
VME Companies to Sell Shares for Offshore Module Work
The Tyler, Texas holding company is seeking public capital to fund project execution, pay down credit lines, and build engineering capacity.
Intermountain Health to Buy Idaho Falls Hospitals in $796.6 Million Deal
Surgery Partners said the sale of Mountain View Hospital and Idaho Falls Community Hospital will make it a pure-play short-stay surgical operator.
Rexford Industrial Closes $1.2 Billion Industrial Portfolio Sale
The Southern California industrial REIT completed a non-core asset sale that advances a $2.0 billion disposition program and is expected to fund 2027 debt repayment and share repurchases.
Gentherm Wins Shareholder Approval for Modine Spin-Off Combination
Gentherm shareholders backed the all-stock Reverse Morris Trust with Modine’s Performance Technologies unit, clearing the last major hurdle before an October 1 close.
Bank of America to Buy Mechanics Auto Loan Runoff
Mechanics Bancorp said the sale of the substantial majority of runoff auto loans will reduce risk, improve liquidity and enhance future profitability.
Interparfums Extends Cavalli Fragrance License Through 2046
The fragrance licensee locked in worldwide rights to Roberto Cavalli and Just Cavalli for another two decades after three years of managing the brands.
Colony to Buy First Reliance in $163 Million Mixed Deal
The combined Southeast community bank is expected to have about $5 billion in assets and a fourth-quarter close.
Atlanticus to Sell CAR Auto Finance in $71.2 Million Deal
The consumer-loan servicer said cash from the sale will reduce debt and fund higher-growth consumer-credit products.
EcoPro expands battery material and environmental sectors
The battery materials division accounted for 72.1% of consolidated revenue.
BioMérieux Net Income Rises 4.7% in First Half 2019
The diagnostics company grew its contributory operating income to 198 million euros while expanding its molecular diagnostic footprint.
BioMérieux Net Income Rises 23% in First Half 2020
The diagnostic company saw a significant increase in free cash flow and operating results driven by molecular biology demand.